JPRN-jRCT2080223664
Unknown
Phase 2
A Phase II Study to Assess the Immunogenicity and Safety of DNK-651 in Japanese over 13 years old.
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- DENKA SEIKEN CO.,LTD.
- Enrollment
- 500
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Japanese over 13 years old
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a H1N1 Influenza Vaccine in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers - Focetria TxVaccination for H1N1sw of immunocompromised adults who have undergone solid organ or bone marrow transplantation and of healthy adultsMedDRA version: 12.1Level: LLTClassification code 10022000Term: InfluenzaEUCTR2009-017052-27-DEMedizinische Hochschule Hannover
Active, not recruiting
Not Applicable
A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a Seasonal Influenza Vaccine including H1N1 in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers - Fluad TxEUCTR2010-022871-78-DEMedizinische Hochschule Hannover
Active, not recruiting
Not Applicable
A Phase II trial evaluating the immunological and clinical efficay and safety of HER-2 Protein Autovac(TM) monotherapy in patients with metastatic breast cancer - NAFemale patients with histologically proven metastatic or locally advanced breast cancer who have HER-2 overexpression in the primary tumour and/or a metastatic lesion.EUCTR2004-000838-36-HUPharmexa A/S60
Active, not recruiting
Not Applicable
A Phase II trial evaluating the immunological and clinical efficacy and safety of HER-2 Protein AutoVac(TM) and Stimulon® Adjuvant QS-21 monotherapy in patients with metastatic breast cancerEUCTR2005-000558-60-HUPharmexa A/S60
Active, not recruiting
Phase 1
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy AdolescentsHealthy volunteers (active immunization against invasive meningococcal disease (IMD) caused by Meningococcal serogroups A, C, Y or WTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2016-001963-35-Outside-EU/EEASanofi Pasteur Inc.1,715